Immunotherapeutic Targeting of AML

Ibraheem Motabi; Bader Alahmari; John F. Dipersio

doi:10.1007/978-981-99-3810-0_15

Immunotherapeutic Targeting of AML

Ibraheem Motabi, Bader Alahmari, John F. Dipersio

Research output: Chapter in Book/Report/Conference proceeding › Chapter › peer-review

Abstract

The use of immunotherapy has revolutionized the field of cancer management. Patients with acute myeloid leukemia (AML) have a defective bone marrow immune environment. Understanding mechanisms of immunoediting and immune escape of AML are key for development of effective immunotherapy for AML. Multiple immunotherapeutic approaches for AML have been under development over the past few years and some are advancing toward late-stage clinical testing. In this chapter we will review our latest understanding of AML immune escape mechanisms and the latest clinical results of immunotherapeutic agents for AML, with focus in monoclonal and bispecific antibodies, adoptive cellular therapy, vaccines, and checkpoint inhibitors.

Original language	English
Title of host publication	Pathogenesis and Treatment of Leukemia
Publisher	Springer Nature
Pages	175-191
Number of pages	17
ISBN (Electronic)	9789819938100
ISBN (Print)	9789819938094
DOIs	https://doi.org/10.1007/978-981-99-3810-0_15
State	Published - Jan 1 2023

Keywords

Acute myeloid leukemia (AML)
Bispecific antibody
Checkpoint inhibitor
Immunotherapy Immune escape
Monoclonal antibody

Access to Document

10.1007/978-981-99-3810-0_15

Cite this

@inbook{6710bbf0e9164161b9eae5d7a89ab3ac,

title = "Immunotherapeutic Targeting of AML",

abstract = "The use of immunotherapy has revolutionized the field of cancer management. Patients with acute myeloid leukemia (AML) have a defective bone marrow immune environment. Understanding mechanisms of immunoediting and immune escape of AML are key for development of effective immunotherapy for AML. Multiple immunotherapeutic approaches for AML have been under development over the past few years and some are advancing toward late-stage clinical testing. In this chapter we will review our latest understanding of AML immune escape mechanisms and the latest clinical results of immunotherapeutic agents for AML, with focus in monoclonal and bispecific antibodies, adoptive cellular therapy, vaccines, and checkpoint inhibitors.",

keywords = "Acute myeloid leukemia (AML), Bispecific antibody, Checkpoint inhibitor, Immunotherapy Immune escape, Monoclonal antibody",

author = "Ibraheem Motabi and Bader Alahmari and Dipersio, {John F.}",

note = "Publisher Copyright: {\textcopyright} The Editor(s) (if applicable) and The Author(s), under exclusive license to Springer Nature Singapore Pte Ltd. 2023, corrected publication 2023.",

year = "2023",

month = jan,

day = "1",

doi = "10.1007/978-981-99-3810-0_15",

language = "English",

isbn = "9789819938094",

pages = "175--191",

booktitle = "Pathogenesis and Treatment of Leukemia",

publisher = "Springer Nature",

}

TY - CHAP

T1 - Immunotherapeutic Targeting of AML

AU - Motabi, Ibraheem

AU - Alahmari, Bader

AU - Dipersio, John F.

N1 - Publisher Copyright: © The Editor(s) (if applicable) and The Author(s), under exclusive license to Springer Nature Singapore Pte Ltd. 2023, corrected publication 2023.

PY - 2023/1/1

Y1 - 2023/1/1

N2 - The use of immunotherapy has revolutionized the field of cancer management. Patients with acute myeloid leukemia (AML) have a defective bone marrow immune environment. Understanding mechanisms of immunoediting and immune escape of AML are key for development of effective immunotherapy for AML. Multiple immunotherapeutic approaches for AML have been under development over the past few years and some are advancing toward late-stage clinical testing. In this chapter we will review our latest understanding of AML immune escape mechanisms and the latest clinical results of immunotherapeutic agents for AML, with focus in monoclonal and bispecific antibodies, adoptive cellular therapy, vaccines, and checkpoint inhibitors.

AB - The use of immunotherapy has revolutionized the field of cancer management. Patients with acute myeloid leukemia (AML) have a defective bone marrow immune environment. Understanding mechanisms of immunoediting and immune escape of AML are key for development of effective immunotherapy for AML. Multiple immunotherapeutic approaches for AML have been under development over the past few years and some are advancing toward late-stage clinical testing. In this chapter we will review our latest understanding of AML immune escape mechanisms and the latest clinical results of immunotherapeutic agents for AML, with focus in monoclonal and bispecific antibodies, adoptive cellular therapy, vaccines, and checkpoint inhibitors.

KW - Acute myeloid leukemia (AML)

KW - Bispecific antibody

KW - Checkpoint inhibitor

KW - Immunotherapy Immune escape

KW - Monoclonal antibody

UR - http://www.scopus.com/inward/record.url?scp=85209020892&partnerID=8YFLogxK

U2 - 10.1007/978-981-99-3810-0_15

DO - 10.1007/978-981-99-3810-0_15

M3 - Chapter

AN - SCOPUS:85209020892

SN - 9789819938094

SP - 175

EP - 191

BT - Pathogenesis and Treatment of Leukemia

PB - Springer Nature

ER -

Immunotherapeutic Targeting of AML

Abstract

Keywords

Access to Document

Other files and links

Fingerprint

Cite this